# MyDRUG (NCT03732703)

> Myeloma-Developing Regimens Using Genomics (MyDRUG)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03732703
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Multiple Myeloma Research Consortium
- Conditions: Relapsed Refractory Multiple Myeloma
- Interventions: Abemaciclib, dexamethasone, ixazomib, pomalidomide; Enasidenib, dexamethasone, ixazomib, pomalidomide; Cobimetinib, dexamethasone, ixazomib, pomalidomide; Erdafitinib, dexamethasone, ixazomib, pomalidomide; Venetoclax, dexamethasone, ixazomib, pomalidomide; Daratumumab, dexamethasone, ixazomib, pomalidomide; Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide; Selinexor, dexamethasone, ixazomib, pomalidomide
- Enrollment: 103
- Primary outcome: Overall Response Rate - Actionable Genetic Alteration
- Primary outcome: Overall Response Rate - Non-Actionable Genetic Alteration

## Commentary we found

- YouTube: 8
- X threads: 4
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=mydrug-nct03732703

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03732703", "email": "<work email>"}; the inbox owner confirms by the emailed link.